Summary & Overview
CPT 0821T: Concurrent In-Person Monitoring During Psychedelic Medication Therapy
CPT code 0821T designates an hourly service in which a second physician or other qualified healthcare professional (QHP) provides continuous, in-person monitoring and intervention concurrent with a primary clinician during psychedelic medication therapy. The code recognizes the need for an additional clinician to manage potential emotional and physiological events that may occur during these sessions and establishes a billing mechanism for that dedicated, hourly presence. Nationally, this code matters as psychedelic-assisted therapies expand in clinical settings and payers evaluate coverage and payment policies for multi-clinician care models.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how the code is defined, typical service settings and clinical rationale, and which payers are relevant to coverage discussions. The publication also summarizes expected benchmarking topics, potential policy considerations affecting adoption, and the clinical context for physician staffing during psychedelic medication sessions.
Data not available in the input for specific modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service-line billing detail. The report focuses on the code definition, service implications, and payer landscape at a national level.
Billing Code Overview
CPT code 0821T describes a second physician or other qualified healthcare professional (QHP) who provides continuous, in-person monitoring and intervention concurrent with a first physician or QHP during a patient’s psychedelic medication therapy. This service is reported per hour and is intended to address potential emotional and physiological issues that can arise during the therapy.
Service Type: Concurrent in-person monitoring and intervention during psychedelic medication therapy
Typical Site of Service: Behavioral health or procedural setting where supervised psychedelic-assisted therapy is delivered, including inpatient or outpatient treatment areas staffed for continuous monitoring
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient with treatment-resistant major depressive disorder undergoes a supervised psychedelic-assisted medication session in an outpatient behavioral health center. The treatment team includes a physician who administers the psychedelic medication and leads the therapeutic process, while a second qualified healthcare professional provides continuous, in-person monitoring and immediate intervention throughout the session due to potential emotional and physiological effects. The second clinician remains in the room for the entire hour-long monitoring period, observes vital signs and mental status, manages acute anxiety or agitation, provides grounding and safety measures, and coordinates emergency escalation to medical staff if needed. Typical workflow steps: intake and consent, baseline vitals and mental status, medication administration by the lead clinician, concurrent in-person monitoring billed per hour using 0821T, ongoing documentation of interventions and patient responses, post-session recovery and discharge instructions, and billing with appropriate modifiers for concurrent service, time units, and any unusual circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
62 | Two surgeons or co-surgeons | Use when two physicians of different specialties provide concurrent intra-procedural roles; applicable if two physicians equally share operative responsibilities during an invasive procedure associated with psychedelic therapy (rare). |
QK | Medical direction of two or more CRNAs by a physician | Use if the supervising physician directs multiple anesthesia professionals during medication administration requiring anesthesia services. |
QX | CRNA service with medical direction by a physician | Use when a CRNA provides the concurrent monitoring under physician direction. |
QY | Medical direction of one CRNA by a physician | Use when one CRNA is medically directed while providing in-person monitoring. |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist – mandated services | Use when the second clinician is an assistant-type provider in a facility-specific required role. |
CQ | Service by a respiratory therapist or similar clinical staff | Use when monitoring includes respiratory therapeutic interventions billed separately or noted for concurrent support. |
22 | Increased procedural services | Use when the monitoring requires substantially greater work, complexity, or risk than typical (document justification). |
52 | Reduced services | Use when the procedure or monitoring is partially reduced or discontinued and not performed as fully described. |
53 | Discontinued procedure | Use when monitoring or the session is terminated due to patient instability before completion. |
56 | Preoperative management only | Use if the clinician provided only pre-session preparation and not concurrent in-person monitoring. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
103K00000X | Psychiatrist | Psychiatrists commonly lead and co-monitor psychedelic-assisted medication therapy. |
207RC0000X | Anesthesiology | Anesthesiologists or CRNAs may provide physiologic monitoring and medication management during sessions. |
362A00000X | Psychologist | Psychologists frequently serve as co-therapists and in-person monitors for psychological safety and therapeutic support. |
363L00000X | Clinical Social Worker | Clinical social workers provide in-person monitoring, integration support, and crisis intervention. |
374P00000X | Nurse Practitioner | Nurse practitioners commonly act as co-monitoring clinicians and can bill for concurrent monitoring services. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
F33.2 | Major depressive disorder, recurrent severe without psychotic features | A common indication for psychedelic-assisted medication therapy; monitoring addresses emotional lability and safety. |
F41.1 | Generalized anxiety disorder | Anxiety disorders are frequently treated in investigational or clinic-based psychedelic therapy programs; monitoring manages acute anxiety responses. |
F32.1 | Major depressive disorder, single episode, moderate | May be treated with psychedelic approaches in select clinical settings; monitoring captures mood and physiologic changes. |
F43.21 | Adjustment disorder with depressed mood | Patients with significant mood symptoms may receive monitored psychedelic interventions when indicated. |
F20.9 | Schizophrenia, unspecified | Generally a contraindication; included here to document careful screening and monitoring considerations if present (rare and typically excluded). |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
0038T | Drug administration, psychedelic-assisted therapy, per session | Used for the medication administration portion typically billed separately from concurrent monitoring; precedes the monitoring hours billed with 0821T. |
90834 | Psychotherapy, 45 minutes with patient | Used for psychotherapy sessions before or after medication sessions as part of the therapeutic package; adjunct to in-person monitoring. |
99223 | Initial hospital care, typically 70 minutes | May be used if the patient requires hospital-level medical evaluation and management related to complications during therapy. |
99152 | Moderate sedation services provided by the same physician performing a procedure | Relevant if moderate sedation is used during medication administration and the same provider also monitors sedation. |
99024 | Postoperative follow-up visit, global service period not ended | Used for medically necessary post-session follow-up related to the psychedelic therapy when outside global billing rules. |